INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7501, 516, 'Metoclopramide', 'Gastrointestinal Diseases', 'The use of metoclopramide is contraindicated in patients with conditions where stimulation of gastrointestinal motility might be harmful, such as mechanical bowel obstruction, bowel perforation, or gastrointestinal hemorrhage.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7502, 2797, 'Metoclopramide', 'Gastrointestinal Diseases', 'The use of metoclopramide is contraindicated in patients with conditions where stimulation of gastrointestinal motility might be harmful, such as mechanical bowel obstruction, bowel perforation, or gastrointestinal hemorrhage.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7503, 7824, 'Metoclopramide', 'Gastrointestinal Diseases', 'The use of metoclopramide is contraindicated in patients with conditions where stimulation of gastrointestinal motility might be harmful, such as mechanical bowel obstruction, bowel perforation, or gastrointestinal hemorrhage.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7504, 7825, 'Metoclopramide', 'Gastrointestinal Diseases', 'The use of metoclopramide is contraindicated in patients with conditions where stimulation of gastrointestinal motility might be harmful, such as mechanical bowel obstruction, bowel perforation, or gastrointestinal hemorrhage.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7505, 7826, 'Metoclopramide', 'Gastrointestinal Diseases', 'The use of metoclopramide is contraindicated in patients with conditions where stimulation of gastrointestinal motility might be harmful, such as mechanical bowel obstruction, bowel perforation, or gastrointestinal hemorrhage.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7506, 7827, 'Metoclopramide', 'Gastrointestinal Diseases', 'The use of metoclopramide is contraindicated in patients with conditions where stimulation of gastrointestinal motility might be harmful, such as mechanical bowel obstruction, bowel perforation, or gastrointestinal hemorrhage.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7507, 7828, 'Metoclopramide', 'Gastrointestinal Diseases', 'The use of metoclopramide is contraindicated in patients with conditions where stimulation of gastrointestinal motility might be harmful, such as mechanical bowel obstruction, bowel perforation, or gastrointestinal hemorrhage.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7508, 8097, 'Metoclopramide', 'Gastrointestinal Diseases', 'The use of metoclopramide is contraindicated in patients with conditions where stimulation of gastrointestinal motility might be harmful, such as mechanical bowel obstruction, bowel perforation, or gastrointestinal hemorrhage.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7509, 25000, 'Metoclopramide', 'Gastrointestinal Diseases', 'The use of metoclopramide is contraindicated in patients with conditions where stimulation of gastrointestinal motility might be harmful, such as mechanical bowel obstruction, bowel perforation, or gastrointestinal hemorrhage.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7510, 25001, 'Metoclopramide', 'Gastrointestinal Diseases', 'The use of metoclopramide is contraindicated in patients with conditions where stimulation of gastrointestinal motility might be harmful, such as mechanical bowel obstruction, bowel perforation, or gastrointestinal hemorrhage.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7511, 25002, 'Metoclopramide', 'Gastrointestinal Diseases', 'The use of metoclopramide is contraindicated in patients with conditions where stimulation of gastrointestinal motility might be harmful, such as mechanical bowel obstruction, bowel perforation, or gastrointestinal hemorrhage.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7512, 25257, 'Metoclopramide', 'Gastrointestinal Diseases', 'The use of metoclopramide is contraindicated in patients with conditions where stimulation of gastrointestinal motility might be harmful, such as mechanical bowel obstruction, bowel perforation, or gastrointestinal hemorrhage.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7513, 25259, 'Metoclopramide', 'Gastrointestinal Diseases', 'The use of metoclopramide is contraindicated in patients with conditions where stimulation of gastrointestinal motility might be harmful, such as mechanical bowel obstruction, bowel perforation, or gastrointestinal hemorrhage.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7514, 25261, 'Metoclopramide', 'Gastrointestinal Diseases', 'The use of metoclopramide is contraindicated in patients with conditions where stimulation of gastrointestinal motility might be harmful, such as mechanical bowel obstruction, bowel perforation, or gastrointestinal hemorrhage.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7515, 27683, 'Metoclopramide', 'Gastrointestinal Diseases', 'The use of metoclopramide is contraindicated in patients with conditions where stimulation of gastrointestinal motility might be harmful, such as mechanical bowel obstruction, bowel perforation, or gastrointestinal hemorrhage.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7516, 29582, 'Metoclopramide', 'Gastrointestinal Diseases', 'The use of metoclopramide is contraindicated in patients with conditions where stimulation of gastrointestinal motility might be harmful, such as mechanical bowel obstruction, bowel perforation, or gastrointestinal hemorrhage.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7517, 29583, 'Metoclopramide', 'Gastrointestinal Diseases', 'The use of metoclopramide is contraindicated in patients with conditions where stimulation of gastrointestinal motility might be harmful, such as mechanical bowel obstruction, bowel perforation, or gastrointestinal hemorrhage.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7518, 516, 'Metoclopramide', 'Neuroleptic Malignant Syndrome', 'Although not a neuroleptic agent, metoclopramide has antidopaminergic effects and may rarely precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, involuntary movements, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Metoclopramide therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of metoclopramide or other antidopaminergic therapy should be carefully considered, since NMS may recur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7519, 2797, 'Metoclopramide', 'Neuroleptic Malignant Syndrome', 'Although not a neuroleptic agent, metoclopramide has antidopaminergic effects and may rarely precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, involuntary movements, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Metoclopramide therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of metoclopramide or other antidopaminergic therapy should be carefully considered, since NMS may recur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7520, 7824, 'Metoclopramide', 'Neuroleptic Malignant Syndrome', 'Although not a neuroleptic agent, metoclopramide has antidopaminergic effects and may rarely precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, involuntary movements, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Metoclopramide therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of metoclopramide or other antidopaminergic therapy should be carefully considered, since NMS may recur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7521, 7825, 'Metoclopramide', 'Neuroleptic Malignant Syndrome', 'Although not a neuroleptic agent, metoclopramide has antidopaminergic effects and may rarely precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, involuntary movements, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Metoclopramide therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of metoclopramide or other antidopaminergic therapy should be carefully considered, since NMS may recur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7522, 7826, 'Metoclopramide', 'Neuroleptic Malignant Syndrome', 'Although not a neuroleptic agent, metoclopramide has antidopaminergic effects and may rarely precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, involuntary movements, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Metoclopramide therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of metoclopramide or other antidopaminergic therapy should be carefully considered, since NMS may recur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7523, 7827, 'Metoclopramide', 'Neuroleptic Malignant Syndrome', 'Although not a neuroleptic agent, metoclopramide has antidopaminergic effects and may rarely precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, involuntary movements, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Metoclopramide therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of metoclopramide or other antidopaminergic therapy should be carefully considered, since NMS may recur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7524, 7828, 'Metoclopramide', 'Neuroleptic Malignant Syndrome', 'Although not a neuroleptic agent, metoclopramide has antidopaminergic effects and may rarely precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, involuntary movements, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Metoclopramide therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of metoclopramide or other antidopaminergic therapy should be carefully considered, since NMS may recur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7525, 8097, 'Metoclopramide', 'Neuroleptic Malignant Syndrome', 'Although not a neuroleptic agent, metoclopramide has antidopaminergic effects and may rarely precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, involuntary movements, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Metoclopramide therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of metoclopramide or other antidopaminergic therapy should be carefully considered, since NMS may recur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7526, 25000, 'Metoclopramide', 'Neuroleptic Malignant Syndrome', 'Although not a neuroleptic agent, metoclopramide has antidopaminergic effects and may rarely precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, involuntary movements, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Metoclopramide therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of metoclopramide or other antidopaminergic therapy should be carefully considered, since NMS may recur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7527, 25001, 'Metoclopramide', 'Neuroleptic Malignant Syndrome', 'Although not a neuroleptic agent, metoclopramide has antidopaminergic effects and may rarely precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, involuntary movements, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Metoclopramide therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of metoclopramide or other antidopaminergic therapy should be carefully considered, since NMS may recur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7528, 25002, 'Metoclopramide', 'Neuroleptic Malignant Syndrome', 'Although not a neuroleptic agent, metoclopramide has antidopaminergic effects and may rarely precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, involuntary movements, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Metoclopramide therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of metoclopramide or other antidopaminergic therapy should be carefully considered, since NMS may recur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7529, 25257, 'Metoclopramide', 'Neuroleptic Malignant Syndrome', 'Although not a neuroleptic agent, metoclopramide has antidopaminergic effects and may rarely precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, involuntary movements, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Metoclopramide therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of metoclopramide or other antidopaminergic therapy should be carefully considered, since NMS may recur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7530, 25259, 'Metoclopramide', 'Neuroleptic Malignant Syndrome', 'Although not a neuroleptic agent, metoclopramide has antidopaminergic effects and may rarely precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, involuntary movements, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Metoclopramide therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of metoclopramide or other antidopaminergic therapy should be carefully considered, since NMS may recur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7531, 25261, 'Metoclopramide', 'Neuroleptic Malignant Syndrome', 'Although not a neuroleptic agent, metoclopramide has antidopaminergic effects and may rarely precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, involuntary movements, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Metoclopramide therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of metoclopramide or other antidopaminergic therapy should be carefully considered, since NMS may recur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7532, 27683, 'Metoclopramide', 'Neuroleptic Malignant Syndrome', 'Although not a neuroleptic agent, metoclopramide has antidopaminergic effects and may rarely precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, involuntary movements, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Metoclopramide therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of metoclopramide or other antidopaminergic therapy should be carefully considered, since NMS may recur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7533, 29582, 'Metoclopramide', 'Neuroleptic Malignant Syndrome', 'Although not a neuroleptic agent, metoclopramide has antidopaminergic effects and may rarely precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, involuntary movements, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Metoclopramide therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of metoclopramide or other antidopaminergic therapy should be carefully considered, since NMS may recur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7534, 29583, 'Metoclopramide', 'Neuroleptic Malignant Syndrome', 'Although not a neuroleptic agent, metoclopramide has antidopaminergic effects and may rarely precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, involuntary movements, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Metoclopramide therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of metoclopramide or other antidopaminergic therapy should be carefully considered, since NMS may recur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7535, 516, 'Metoclopramide', 'Pheochromocytoma', 'The use of metoclopramide is contraindicated in patients with pheochromocytoma.  In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Hypertensive crises may occur in patients with pheochromocytoma due to induction of catecholamine release from the tumor.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7536, 2797, 'Metoclopramide', 'Pheochromocytoma', 'The use of metoclopramide is contraindicated in patients with pheochromocytoma.  In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Hypertensive crises may occur in patients with pheochromocytoma due to induction of catecholamine release from the tumor.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7537, 7824, 'Metoclopramide', 'Pheochromocytoma', 'The use of metoclopramide is contraindicated in patients with pheochromocytoma.  In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Hypertensive crises may occur in patients with pheochromocytoma due to induction of catecholamine release from the tumor.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7538, 7825, 'Metoclopramide', 'Pheochromocytoma', 'The use of metoclopramide is contraindicated in patients with pheochromocytoma.  In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Hypertensive crises may occur in patients with pheochromocytoma due to induction of catecholamine release from the tumor.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7539, 7826, 'Metoclopramide', 'Pheochromocytoma', 'The use of metoclopramide is contraindicated in patients with pheochromocytoma.  In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Hypertensive crises may occur in patients with pheochromocytoma due to induction of catecholamine release from the tumor.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7540, 7827, 'Metoclopramide', 'Pheochromocytoma', 'The use of metoclopramide is contraindicated in patients with pheochromocytoma.  In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Hypertensive crises may occur in patients with pheochromocytoma due to induction of catecholamine release from the tumor.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7541, 7828, 'Metoclopramide', 'Pheochromocytoma', 'The use of metoclopramide is contraindicated in patients with pheochromocytoma.  In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Hypertensive crises may occur in patients with pheochromocytoma due to induction of catecholamine release from the tumor.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7542, 8097, 'Metoclopramide', 'Pheochromocytoma', 'The use of metoclopramide is contraindicated in patients with pheochromocytoma.  In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Hypertensive crises may occur in patients with pheochromocytoma due to induction of catecholamine release from the tumor.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7543, 25000, 'Metoclopramide', 'Pheochromocytoma', 'The use of metoclopramide is contraindicated in patients with pheochromocytoma.  In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Hypertensive crises may occur in patients with pheochromocytoma due to induction of catecholamine release from the tumor.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7544, 25001, 'Metoclopramide', 'Pheochromocytoma', 'The use of metoclopramide is contraindicated in patients with pheochromocytoma.  In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Hypertensive crises may occur in patients with pheochromocytoma due to induction of catecholamine release from the tumor.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7545, 25002, 'Metoclopramide', 'Pheochromocytoma', 'The use of metoclopramide is contraindicated in patients with pheochromocytoma.  In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Hypertensive crises may occur in patients with pheochromocytoma due to induction of catecholamine release from the tumor.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7546, 25257, 'Metoclopramide', 'Pheochromocytoma', 'The use of metoclopramide is contraindicated in patients with pheochromocytoma.  In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Hypertensive crises may occur in patients with pheochromocytoma due to induction of catecholamine release from the tumor.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7547, 25259, 'Metoclopramide', 'Pheochromocytoma', 'The use of metoclopramide is contraindicated in patients with pheochromocytoma.  In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Hypertensive crises may occur in patients with pheochromocytoma due to induction of catecholamine release from the tumor.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7548, 25261, 'Metoclopramide', 'Pheochromocytoma', 'The use of metoclopramide is contraindicated in patients with pheochromocytoma.  In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Hypertensive crises may occur in patients with pheochromocytoma due to induction of catecholamine release from the tumor.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7549, 27683, 'Metoclopramide', 'Pheochromocytoma', 'The use of metoclopramide is contraindicated in patients with pheochromocytoma.  In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Hypertensive crises may occur in patients with pheochromocytoma due to induction of catecholamine release from the tumor.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7550, 29582, 'Metoclopramide', 'Pheochromocytoma', 'The use of metoclopramide is contraindicated in patients with pheochromocytoma.  In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Hypertensive crises may occur in patients with pheochromocytoma due to induction of catecholamine release from the tumor.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7551, 29583, 'Metoclopramide', 'Pheochromocytoma', 'The use of metoclopramide is contraindicated in patients with pheochromocytoma.  In a study involving patients with essential hypertension, intravenously administered metoclopramide was shown to induce the release of catecholamines.  Hypertensive crises may occur in patients with pheochromocytoma due to induction of catecholamine release from the tumor.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7552, 516, 'Metoclopramide', 'Seizures', 'The use of metoclopramide is contraindicated in patients with seizure disorders.  Metoclopramide may increase the frequency and severity of seizures.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7553, 2797, 'Metoclopramide', 'Seizures', 'The use of metoclopramide is contraindicated in patients with seizure disorders.  Metoclopramide may increase the frequency and severity of seizures.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7554, 7824, 'Metoclopramide', 'Seizures', 'The use of metoclopramide is contraindicated in patients with seizure disorders.  Metoclopramide may increase the frequency and severity of seizures.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7555, 7825, 'Metoclopramide', 'Seizures', 'The use of metoclopramide is contraindicated in patients with seizure disorders.  Metoclopramide may increase the frequency and severity of seizures.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7556, 7826, 'Metoclopramide', 'Seizures', 'The use of metoclopramide is contraindicated in patients with seizure disorders.  Metoclopramide may increase the frequency and severity of seizures.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7557, 7827, 'Metoclopramide', 'Seizures', 'The use of metoclopramide is contraindicated in patients with seizure disorders.  Metoclopramide may increase the frequency and severity of seizures.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7558, 7828, 'Metoclopramide', 'Seizures', 'The use of metoclopramide is contraindicated in patients with seizure disorders.  Metoclopramide may increase the frequency and severity of seizures.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7559, 8097, 'Metoclopramide', 'Seizures', 'The use of metoclopramide is contraindicated in patients with seizure disorders.  Metoclopramide may increase the frequency and severity of seizures.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7560, 25000, 'Metoclopramide', 'Seizures', 'The use of metoclopramide is contraindicated in patients with seizure disorders.  Metoclopramide may increase the frequency and severity of seizures.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7561, 25001, 'Metoclopramide', 'Seizures', 'The use of metoclopramide is contraindicated in patients with seizure disorders.  Metoclopramide may increase the frequency and severity of seizures.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7562, 25002, 'Metoclopramide', 'Seizures', 'The use of metoclopramide is contraindicated in patients with seizure disorders.  Metoclopramide may increase the frequency and severity of seizures.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7563, 25257, 'Metoclopramide', 'Seizures', 'The use of metoclopramide is contraindicated in patients with seizure disorders.  Metoclopramide may increase the frequency and severity of seizures.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7564, 25259, 'Metoclopramide', 'Seizures', 'The use of metoclopramide is contraindicated in patients with seizure disorders.  Metoclopramide may increase the frequency and severity of seizures.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7565, 25261, 'Metoclopramide', 'Seizures', 'The use of metoclopramide is contraindicated in patients with seizure disorders.  Metoclopramide may increase the frequency and severity of seizures.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7566, 27683, 'Metoclopramide', 'Seizures', 'The use of metoclopramide is contraindicated in patients with seizure disorders.  Metoclopramide may increase the frequency and severity of seizures.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7567, 29582, 'Metoclopramide', 'Seizures', 'The use of metoclopramide is contraindicated in patients with seizure disorders.  Metoclopramide may increase the frequency and severity of seizures.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7568, 29583, 'Metoclopramide', 'Seizures', 'The use of metoclopramide is contraindicated in patients with seizure disorders.  Metoclopramide may increase the frequency and severity of seizures.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7569, 516, 'Metoclopramide', 'Tardive Dyskinesia', 'Metoclopramide may precipitate symptoms of tardive dyskinesia (TD) following chronic administration.  Elderly patients, particularly women, are most susceptible.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of metoclopramide or other antidopaminergic therapy administered.  Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia.  There is no known treatment for tardive dyskinesia.  In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.  Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of metoclopramide therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7570, 2797, 'Metoclopramide', 'Tardive Dyskinesia', 'Metoclopramide may precipitate symptoms of tardive dyskinesia (TD) following chronic administration.  Elderly patients, particularly women, are most susceptible.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of metoclopramide or other antidopaminergic therapy administered.  Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia.  There is no known treatment for tardive dyskinesia.  In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.  Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of metoclopramide therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7571, 7824, 'Metoclopramide', 'Tardive Dyskinesia', 'Metoclopramide may precipitate symptoms of tardive dyskinesia (TD) following chronic administration.  Elderly patients, particularly women, are most susceptible.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of metoclopramide or other antidopaminergic therapy administered.  Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia.  There is no known treatment for tardive dyskinesia.  In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.  Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of metoclopramide therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7572, 7825, 'Metoclopramide', 'Tardive Dyskinesia', 'Metoclopramide may precipitate symptoms of tardive dyskinesia (TD) following chronic administration.  Elderly patients, particularly women, are most susceptible.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of metoclopramide or other antidopaminergic therapy administered.  Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia.  There is no known treatment for tardive dyskinesia.  In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.  Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of metoclopramide therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7573, 7826, 'Metoclopramide', 'Tardive Dyskinesia', 'Metoclopramide may precipitate symptoms of tardive dyskinesia (TD) following chronic administration.  Elderly patients, particularly women, are most susceptible.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of metoclopramide or other antidopaminergic therapy administered.  Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia.  There is no known treatment for tardive dyskinesia.  In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.  Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of metoclopramide therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7574, 7827, 'Metoclopramide', 'Tardive Dyskinesia', 'Metoclopramide may precipitate symptoms of tardive dyskinesia (TD) following chronic administration.  Elderly patients, particularly women, are most susceptible.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of metoclopramide or other antidopaminergic therapy administered.  Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia.  There is no known treatment for tardive dyskinesia.  In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.  Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of metoclopramide therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7575, 7828, 'Metoclopramide', 'Tardive Dyskinesia', 'Metoclopramide may precipitate symptoms of tardive dyskinesia (TD) following chronic administration.  Elderly patients, particularly women, are most susceptible.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of metoclopramide or other antidopaminergic therapy administered.  Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia.  There is no known treatment for tardive dyskinesia.  In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.  Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of metoclopramide therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7576, 8097, 'Metoclopramide', 'Tardive Dyskinesia', 'Metoclopramide may precipitate symptoms of tardive dyskinesia (TD) following chronic administration.  Elderly patients, particularly women, are most susceptible.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of metoclopramide or other antidopaminergic therapy administered.  Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia.  There is no known treatment for tardive dyskinesia.  In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.  Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of metoclopramide therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7577, 25000, 'Metoclopramide', 'Tardive Dyskinesia', 'Metoclopramide may precipitate symptoms of tardive dyskinesia (TD) following chronic administration.  Elderly patients, particularly women, are most susceptible.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of metoclopramide or other antidopaminergic therapy administered.  Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia.  There is no known treatment for tardive dyskinesia.  In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.  Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of metoclopramide therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7578, 25001, 'Metoclopramide', 'Tardive Dyskinesia', 'Metoclopramide may precipitate symptoms of tardive dyskinesia (TD) following chronic administration.  Elderly patients, particularly women, are most susceptible.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of metoclopramide or other antidopaminergic therapy administered.  Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia.  There is no known treatment for tardive dyskinesia.  In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.  Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of metoclopramide therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7579, 25002, 'Metoclopramide', 'Tardive Dyskinesia', 'Metoclopramide may precipitate symptoms of tardive dyskinesia (TD) following chronic administration.  Elderly patients, particularly women, are most susceptible.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of metoclopramide or other antidopaminergic therapy administered.  Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia.  There is no known treatment for tardive dyskinesia.  In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.  Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of metoclopramide therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7580, 25257, 'Metoclopramide', 'Tardive Dyskinesia', 'Metoclopramide may precipitate symptoms of tardive dyskinesia (TD) following chronic administration.  Elderly patients, particularly women, are most susceptible.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of metoclopramide or other antidopaminergic therapy administered.  Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia.  There is no known treatment for tardive dyskinesia.  In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.  Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of metoclopramide therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7581, 25259, 'Metoclopramide', 'Tardive Dyskinesia', 'Metoclopramide may precipitate symptoms of tardive dyskinesia (TD) following chronic administration.  Elderly patients, particularly women, are most susceptible.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of metoclopramide or other antidopaminergic therapy administered.  Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia.  There is no known treatment for tardive dyskinesia.  In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.  Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of metoclopramide therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7582, 25261, 'Metoclopramide', 'Tardive Dyskinesia', 'Metoclopramide may precipitate symptoms of tardive dyskinesia (TD) following chronic administration.  Elderly patients, particularly women, are most susceptible.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of metoclopramide or other antidopaminergic therapy administered.  Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia.  There is no known treatment for tardive dyskinesia.  In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.  Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of metoclopramide therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7583, 27683, 'Metoclopramide', 'Tardive Dyskinesia', 'Metoclopramide may precipitate symptoms of tardive dyskinesia (TD) following chronic administration.  Elderly patients, particularly women, are most susceptible.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of metoclopramide or other antidopaminergic therapy administered.  Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia.  There is no known treatment for tardive dyskinesia.  In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.  Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of metoclopramide therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7584, 29582, 'Metoclopramide', 'Tardive Dyskinesia', 'Metoclopramide may precipitate symptoms of tardive dyskinesia (TD) following chronic administration.  Elderly patients, particularly women, are most susceptible.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of metoclopramide or other antidopaminergic therapy administered.  Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia.  There is no known treatment for tardive dyskinesia.  In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.  Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of metoclopramide therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7585, 29583, 'Metoclopramide', 'Tardive Dyskinesia', 'Metoclopramide may precipitate symptoms of tardive dyskinesia (TD) following chronic administration.  Elderly patients, particularly women, are most susceptible.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of metoclopramide or other antidopaminergic therapy administered.  Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia.  There is no known treatment for tardive dyskinesia.  In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.  Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of metoclopramide therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7586, 516, 'Metoclopramide', 'Water-Electrolyte Imbalance', 'Metoclopramide produces a transient increase in plasma aldosterone and may cause fluid retention and volume overload in susceptible patients.  Therapy with metoclopramide should be administered cautiously in patients with or at risk for fluid overload (e.g., cirrhosis, congestive heart failure).  If these side effects occur at any time during metoclopramide therapy, the drug should be discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7587, 2797, 'Metoclopramide', 'Water-Electrolyte Imbalance', 'Metoclopramide produces a transient increase in plasma aldosterone and may cause fluid retention and volume overload in susceptible patients.  Therapy with metoclopramide should be administered cautiously in patients with or at risk for fluid overload (e.g., cirrhosis, congestive heart failure).  If these side effects occur at any time during metoclopramide therapy, the drug should be discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7588, 7824, 'Metoclopramide', 'Water-Electrolyte Imbalance', 'Metoclopramide produces a transient increase in plasma aldosterone and may cause fluid retention and volume overload in susceptible patients.  Therapy with metoclopramide should be administered cautiously in patients with or at risk for fluid overload (e.g., cirrhosis, congestive heart failure).  If these side effects occur at any time during metoclopramide therapy, the drug should be discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7589, 7825, 'Metoclopramide', 'Water-Electrolyte Imbalance', 'Metoclopramide produces a transient increase in plasma aldosterone and may cause fluid retention and volume overload in susceptible patients.  Therapy with metoclopramide should be administered cautiously in patients with or at risk for fluid overload (e.g., cirrhosis, congestive heart failure).  If these side effects occur at any time during metoclopramide therapy, the drug should be discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7590, 7826, 'Metoclopramide', 'Water-Electrolyte Imbalance', 'Metoclopramide produces a transient increase in plasma aldosterone and may cause fluid retention and volume overload in susceptible patients.  Therapy with metoclopramide should be administered cautiously in patients with or at risk for fluid overload (e.g., cirrhosis, congestive heart failure).  If these side effects occur at any time during metoclopramide therapy, the drug should be discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7591, 7827, 'Metoclopramide', 'Water-Electrolyte Imbalance', 'Metoclopramide produces a transient increase in plasma aldosterone and may cause fluid retention and volume overload in susceptible patients.  Therapy with metoclopramide should be administered cautiously in patients with or at risk for fluid overload (e.g., cirrhosis, congestive heart failure).  If these side effects occur at any time during metoclopramide therapy, the drug should be discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7592, 7828, 'Metoclopramide', 'Water-Electrolyte Imbalance', 'Metoclopramide produces a transient increase in plasma aldosterone and may cause fluid retention and volume overload in susceptible patients.  Therapy with metoclopramide should be administered cautiously in patients with or at risk for fluid overload (e.g., cirrhosis, congestive heart failure).  If these side effects occur at any time during metoclopramide therapy, the drug should be discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7593, 8097, 'Metoclopramide', 'Water-Electrolyte Imbalance', 'Metoclopramide produces a transient increase in plasma aldosterone and may cause fluid retention and volume overload in susceptible patients.  Therapy with metoclopramide should be administered cautiously in patients with or at risk for fluid overload (e.g., cirrhosis, congestive heart failure).  If these side effects occur at any time during metoclopramide therapy, the drug should be discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7594, 25000, 'Metoclopramide', 'Water-Electrolyte Imbalance', 'Metoclopramide produces a transient increase in plasma aldosterone and may cause fluid retention and volume overload in susceptible patients.  Therapy with metoclopramide should be administered cautiously in patients with or at risk for fluid overload (e.g., cirrhosis, congestive heart failure).  If these side effects occur at any time during metoclopramide therapy, the drug should be discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7595, 25001, 'Metoclopramide', 'Water-Electrolyte Imbalance', 'Metoclopramide produces a transient increase in plasma aldosterone and may cause fluid retention and volume overload in susceptible patients.  Therapy with metoclopramide should be administered cautiously in patients with or at risk for fluid overload (e.g., cirrhosis, congestive heart failure).  If these side effects occur at any time during metoclopramide therapy, the drug should be discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7596, 25002, 'Metoclopramide', 'Water-Electrolyte Imbalance', 'Metoclopramide produces a transient increase in plasma aldosterone and may cause fluid retention and volume overload in susceptible patients.  Therapy with metoclopramide should be administered cautiously in patients with or at risk for fluid overload (e.g., cirrhosis, congestive heart failure).  If these side effects occur at any time during metoclopramide therapy, the drug should be discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7597, 25257, 'Metoclopramide', 'Water-Electrolyte Imbalance', 'Metoclopramide produces a transient increase in plasma aldosterone and may cause fluid retention and volume overload in susceptible patients.  Therapy with metoclopramide should be administered cautiously in patients with or at risk for fluid overload (e.g., cirrhosis, congestive heart failure).  If these side effects occur at any time during metoclopramide therapy, the drug should be discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7598, 25259, 'Metoclopramide', 'Water-Electrolyte Imbalance', 'Metoclopramide produces a transient increase in plasma aldosterone and may cause fluid retention and volume overload in susceptible patients.  Therapy with metoclopramide should be administered cautiously in patients with or at risk for fluid overload (e.g., cirrhosis, congestive heart failure).  If these side effects occur at any time during metoclopramide therapy, the drug should be discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7599, 25261, 'Metoclopramide', 'Water-Electrolyte Imbalance', 'Metoclopramide produces a transient increase in plasma aldosterone and may cause fluid retention and volume overload in susceptible patients.  Therapy with metoclopramide should be administered cautiously in patients with or at risk for fluid overload (e.g., cirrhosis, congestive heart failure).  If these side effects occur at any time during metoclopramide therapy, the drug should be discontinued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7600, 27683, 'Metoclopramide', 'Water-Electrolyte Imbalance', 'Metoclopramide produces a transient increase in plasma aldosterone and may cause fluid retention and volume overload in susceptible patients.  Therapy with metoclopramide should be administered cautiously in patients with or at risk for fluid overload (e.g., cirrhosis, congestive heart failure).  If these side effects occur at any time during metoclopramide therapy, the drug should be discontinued.', '2', '', 'DDInter', 0);
